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Abstract  
Objective: To investigate the preventive effect of antireflux surgery against 
esophageal adenocarcinoma (EAC), compared to medical treatment of 
gastroesophageal reflux disease (GERD) and to the background population. 
Background: GERD is causally associated with EAC. Effective symptomatic 
treatment can be achieved with medication and antireflux surgery, yet the possible 
preventive effect on EAC development remains unclear. 
Methods: This systematic review identified 10 studies comparing EAC risk following 
antireflux surgery with non-operated GERD patients, including 7 studies of patients 
with Barrett’s esophagus; and 2 studies comparing EAC risk after antireflux surgery 
to the background population. A fixed-effects Poisson meta-analysis was conducted to 
calculate pooled incidence rate ratios (IRR) and 95% confidence intervals (CI).  
Results: The pooled IRR in patients following antireflux surgery was 0.76 (95% CI 
0.42-1.39) compared to medically treated GERD patients. In patients with Barrett’s 
esophagus, the corresponding IRR was 0.46 (95% CI 0.20-1.08), and 0.26 (95% CI 
0.09-0.79) when restricted to publications after 2000. There was no difference in EAC 
risk between antireflux surgery and medical treatment in GERD patients without 
known Barrett’s esophagus (IRR 0.98, 95% CI 0.72-1.33). The EAC risk remained 
elevated in patients following antireflux surgery compared to the background 
population (IRR 10.78, 95% CI 8.48-13.71). While the clinical heterogeneity of the 
included studies was high, the statistical heterogeneity was low.  
Conclusions: Antireflux surgery may prevent EAC better than medical therapy in 
patients with Barrett’s esophagus. The EAC risk following antireflux surgery does not 
seem to revert to that of the background population.  
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Introduction 
Gastroesophageal reflux disease (GERD) is a strong and dose-dependent risk factor 
for esophageal adenocarcinoma (EAC).
1, 2
 The incidence of EAC has increased 
rapidly in the Western world during the last 4 decades, and the prognosis has 
remained poor (<15% survival in Western societies).
3, 4
 Thus, preventive measures are 
highly warranted. Antireflux therapy might be one such measure, but the available 
literature is limited and has failed to establish any conclusive preventive effects 
against EAC. The main treatment options for severe GERD are medical (mainly 
proton pump inhibitors or H2 receptor antagonists) or surgical (various types of 
fundoplication).
5-7
 Two previous meta-analyses of patients with GERD and Barrett’s 
esophagus found no preventive effect of antireflux surgery in the development of 
EAC compared to medical treatment.
8, 9
 However, both these meta-analyses included 
studies evaluating only one treatment and pooled the medically treated patients in one 
group and the surgically treated patients in another. This could lead to methodological 
difficulties when comparing any preventive effects.
8, 9
 A third, more recent meta-
analysis concluded that antireflux surgery does not prevent EAC in patients with 
Barrett’s esophagus based on a high postoperative tumor progression rate.10 The first 
objective of the present study was to perform a systematic review and meta-analysis 
comparing the risk of EAC in patients following antireflux surgery compared to 
medically treated patients with GERD, with or without Barrett’s esophagus, and only 
include studies with both treatment arms. The second objective was to assess the risk 
of EAC following antireflux surgery compared to the risk of EAC in the 
corresponding background population. 
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Methods 
Study design 
A systematic literature review and meta-analysis was performed, which followed an 
a-priori established study protocol. The results are reported in accordance with the 
PRISMA (‘Preferred Reporting Items for Systematic Reviews and Meta-Analysis’) 
guidelines.
11
 The search aimed to identify all studies addressing the risk of EAC 
following antireflux surgery compared to medication in patients with GERD, with and 
without Barrett’s esophagus, or compared to the background population. All 
definitions of GERD and antireflux surgery were considered eligible for inclusion and 
no language restriction was applied. The time period was from an unbounded start 
date to June 12, 2014. Three scientific search engines were used: PubMed/MedLine 
database, Web of Science, and Cochrane. To identify relevant studies, the following 
search terms were used: esophageal, esophagus, neoplasm, adenocarcinoma, cancer, 
Barrett, fundoplication, antireflux surgery, Nissen, and reflux surgery (taking into 
account different spellings). Backward and forward citation tracking of the identified 
studies was performed by screening reference and citation lists in the Web of Science 
to identify potential additional articles. The selection of relevant articles was 
performed by two investigators separately (JMO and NB) after which all selected 
articles were compared. The final assessment of the eligibility of the articles 
remaining after exclusion of irrelevant articles was performed by all authors.  
 
Study selection 
Studies were included if they provided original data on the incidence of EAC in 
patients with GERD undergoing surgical treatment compared to medically treated 
patients with GERD (with or without Barrett´s esophagus) or the corresponding 
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general background population. To increase statistical power, no restrictions were 
made regarding type of antireflux medication or antireflux surgery procedure. To be 
included, the study needed to have reported the type of intervention performed in each 
comparison group, the incidence of EAC in each group, and the total follow-up time 
(reported or deductible) to enable calculation of incidence rates. Any patients 
developing high-grade dysplasia were included in the EAC group. To be eligible for 
inclusion, there had to be at least 1 reported case of EAC in one or both of the 
comparison groups. Eligible studies included cohort studies, case-control studies and 
intervention studies (randomized clinical trials), and both prospective and 
retrospective studies. Case reports, case series, cross-sectional studies and non-
original articles (e.g. reviews, editorials and comments) were excluded, as were 
animal studies and those without a comparison group. A quality assessment of the 
included articles was based on the methods of selecting study participants, methods 
for measuring the exposure and outcome, sources of bias, methods for controlling for 
potential confounding, and conflicts of interests.
12
 
 
Data synthesis and statistical analysis 
The total number of person-years of the comparison groups were either calculated or 
extracted from the selected articles. The meta-analysis was conducted using the R 
package metaphor.
13, 14
 A fixed-effects Poisson meta-analysis was used to calculate 
the pooled incidence rate ratio (IRR) and 95% confidence intervals (CI).
15
 The IRR 
was considered statistically significant if the 95% CI did not include the number 1, 
which corresponds with no effect. In the statistical model, the studies were weighted 
due to the size of the cohorts. A random effects Poisson meta-analysis showed similar 
results as the fixed-effects Poisson meta-analysis. The included studies were separated 
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into two groups: 1) Antireflux surgery compared to a medicated GERD population 
with and without Barrett’s esophagus, and 2) antireflux surgery compared to the 
corresponding background population. In studies where one of the treatment arms had 
no cases of EAC, we added 0.5 to both treatment arms, an established method 
described in detail elsewhere.
15
 In the 2 included studies using the background 
population as a comparison group, no follow-up time was stated for the background 
population. For one study, the total incidence of EAC for the background population 
was stated, while for the other study this information was retrieved from the authors 
who kindly provided additional data on the background population. Using the 
incidence and the incidence rate, a total follow-up time could be calculated.
16, 17
 
Statistical heterogeneity was assessed by means of an I
2
-test and was categorized into 
low (<50%), moderate (51-75%), or high (>75%) according to pre-defined criteria.
18
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Results 
Included studies 
Among a total of 1,987 unique articles that were considered, 12 met the inclusion 
criteria (Figure 1). These included 7 cohort studies comparing EAC risk in patients 
after antireflux surgery with a medically treated GERD population,
19-25
 1 cohort study 
comparing EAC risk in patients following antireflux surgery without specified 
treatment in a GERD population,
26
 2 randomized clinical trials comparing EAC risk 
in patients after antireflux surgery with medicated GERD patients,
27, 28
 and 2 
population-based studies comparing EAC risk in GERD patients undergoing 
antireflux surgery to the background population.
16, 17
 Of the 10 studies with non-
operated GERD patients as a control group, 7 included patients with Barrett’s 
esophagus.
19-22, 24, 25, 28
 The mean follow-up time varied across studies, ranging from 
1.4 years to 10.6 years (up to 42 years). The clinical heterogeneity in the included 
studies was large as indicated in the quality assessment presented in Figure 2. 
 
Definitions 
GERD and antireflux surgery were identified based on the International Classification 
of Diseases (ICD) versions 7-10 in 3 studies,
17, 23, 26
 while 1 study used the American 
Joint Committee of Cancer (AJCC) criteria for these variables.
16
 The 7 studies of 
Barrett’s esophagus were all based on endoscopic and pathologic evaluation.19-22, 24, 25, 
28
 Nissen fundoplication (360 degree wrap of the stomach around the esophagus) was 
the most frequently used surgical procedure. In the medication groups, proton pump 
inhibitors or H2-receptor antagonists were typically used, although 3 studies did not 
specify the type of medication (Table 1).  
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Antireflux surgery patients versus non-operated patients with GERD or 
Barrett´s esophagus 
The 10 studies in this category were performed in the United States, Spain, Sweden, 
Ireland and the United Kingdom, and included a total of 100,479 person-years in 
patients following antireflux surgery and 403,459 person-years in non-operated 
GERD patients (Table 1). None of the individual studies showed any statistically 
significant differences in risk of EAC between patients after antireflux surgery and 
medically treated GERD patients, but the IRRs of EAC were generally lower in the 
antireflux surgery groups (Figure 3). The meta-analysis of all 10 studies revealed a 
pooled IRR of EAC of 0.89 (95% CI 0.66-1.19, I
2
 0%) comparing fundoplication with 
no fundoplication (Figure 3). After excluding the one study comparing patients after 
antireflux surgery with a GERD population without known treatment, the 
corresponding pooled IRR decreased (IRR 0.76, 95% CI 0.42-1.39, I
2
 0%). The 
analysis of the 7 studies of patients with Barrett’s esophagus showed a decreased 
pooled IRR of EAC in the antireflux surgery group compared to the medically treated 
group (IRR 0.46, 95% CI 0.20-1.08, I
2
 0%). The sub-analysis restricted to the 4 
studies of Barrett’s esophagus published after the year 2000 showed a further 
decreased risk of EAC following antireflux surgery compared to medication (IRR 
0.26, 95% CI 0.09-0.79, I
2
 0%), which reached the threshold of statistical 
significance. An analysis of 3 studies investigating GERD patients without confirmed 
Barrett’s esophagus showed no difference in EAC risk between antireflux surgery and 
medical treatment (IRR 0.98, 95% CI 0.72-1.33, I
2
 0%). The statistical heterogeneity 
in all analyses was low (I
2
= 0%). Subgroup analyses by different types of medication, 
surgical techniques, or study designs were not feasible due to the limited number of 
studies meeting the inclusion criteria. 
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Antireflux surgery patients versus background population 
Two nationwide and population-based cohort studies, from Sweden and Finland, 
compared the risk of developing EAC in patients following antireflux surgery to that 
of the background population after adjustment for age, sex and calendar period.
16, 17
 
The maximum follow-up times were 42 years and 26 years, in the Swedish and 
Finnish studies, respectively. Combining these 2 studies, the total number of person-
years of follow-up was 254,952 and 166,060,651 in the antireflux surgery group and 
in the background population, respectively. Both studies showed a strongly increased 
relative risk of EAC following antireflux surgery that remained increased with longer 
time after surgery, and the meta-analysis revealed a pooled standardized IRR of 10.78 
(95% CI 8.48-13.71, I
2
 0%) (Figure 4).  
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Discussion 
This meta-analysis provided some evidence of a decreased risk of EAC in patients 
following antireflux surgery compared to medicated patients with Barrett’s 
esophagus, but not in GERD patients without Barrett’s. The risk of EAC remained 
elevated in patients after antireflux surgery compared to that of the general 
background population.  
 
A methodological advantage of this study is that it included only studies with two 
separate treatment arms, instead of including multiple studies with only one treatment 
arm. This makes comparisons more reliable, since potential confounding is to some 
extent taken into account due to a similar clinical setting in the comparison groups. 
Weaknesses include the fact that none of the included studies adjusted for duration or 
severity of GERD. However, the comparison groups should have been well balanced 
regarding confounders in the 2 intervention studies due to randomization. The 
statistical heterogeneity was low (I
2
 was 0% in all analyses). However, there was a 
large clinical heterogeneity, since the study characteristics varied considerably. As 
with any meta-analysis, we cannot exclude the possibility that studies were missed 
during our search, or that studies that observed null effects were never published 
(publication bias). Potential influence related to changes in surgical treatment, 
prescription patterns of GERD medication, or duration of follow-up could not be 
assessed due to the lack of such data. In the clinical setting, there might have been 
selection bias in the decision-making, since clinicians might be more prone to 
recommend antireflux surgery to patients with more severe GERD and therefore an 
inherently higher risk of EAC. However, such bias would underestimate any 
protective effect of antireflux surgery against EAC and not contribute to the decreased 
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risk compared to medication, indicated in the present study. Another possible 
limitation is that different definitions for the exposure and outcome were pooled 
together, but again, such misclassification would dilute effects rather than cause them, 
and could thus lead to an underestimation of the decreased IRRs following antireflux 
surgery. Finally, the low number of studies and the typically small sample size and 
limited follow-up time in the included studies lowered the statistical power and 
increased the risk of chance errors. The confidence intervals were wide and even 
strongly decreased risk estimates were not always statistically significant. 
 
In relation to previous meta-analyses on the subject, our meta-analysis had more strict 
inclusion criteria and used different methodology. One meta-analysis only reported 
the incidence of EAC in patients with Barrett’s esophagus following antireflux 
surgery and medication separately, as 3.8/1000 person-years and 5.3/1000 person-
years, respectively, concluding that no difference was found.
8
 However, the 
equivalent of this risk ratio was in fact 0.72 (calculated by us). Moreover, 24 of the 34 
articles included in that study had only one treatment arm. In a more recent meta-
analysis that compared the risk of EAC after antireflux surgery with medication in 
patients with Barrett’s esophagus, 20 of 25 included articles had one treatment arm 
only.
9
 The incidence rate after surgery was 2.8/1000 person-years and 6.3/1000 
person-years after medical treatment.
9
 This is equivalent to a risk ratio as low as 0.44 
(calculated by us). In the most recent meta-analysis, published in 2008, 35 articles 
examining the risk of EAC in operated patients without any comparison group 
concluded that antireflux surgery does not prevent EAC based on a tumor progression 
rate of 3.8% during a mean follow-up time of 57 months.
10
  
12 
 
 
 
Except for the decreased pooled risk estimates of EAC in patients following antireflux 
surgery compared to medication in patients with Barrett’s esophagus, another 
argument in favor of a protective effect of antireflux surgery against EAC is that the 
recent studies all showed an effect size in the same direction. Yet, to establish 
whether any preventive effect against EAC is better following antireflux surgery than 
medication, there is a need for larger studies with long follow-up and adjustment for 
confounders that take duration and severity of GERD into account. As mentioned 
above, there is a risk of selection bias in the included studies. Such a bias would likely 
be more prone towards recommending surgery to patients with more severe GERD 
who are at higher risk of EAC at baseline, and this might lead to an underestimation 
of the possible preventive effect of surgery compared to medication. Since this would 
lead to an underestimation of the effect in the meta-analysis as well, the chance of a 
stronger preventive effect following antireflux surgery cannot be excluded based on 
the available data.  
 
Although medication came out as being less effective than antireflux surgery in 
preventing EAC, this study cannot exclude a preventive effect of medication. While 
individual studies have mostly failed to detect any preventive effect of medication 
against EAC, a recent meta-analysis found a pooled odds ratio as low as 0.29 (95% CI 
0.12-0.79) comparing patients on PPI with unspecified non PPI-users.
29
   
 
The reasons for the potentially stronger preventive role of antireflux surgery for EAC 
compared to medication include the fact that antireflux surgery creates a mechanical 
barrier against all contents included in the refluxed juice, including duodeno-
gastroesophageal reflux of bile and pancreatic juice, which could be particularly 
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harmful from a carcinogenic point of view.
30
 Medical treatment does not prevent such 
reflux per se, but mainly decreases the acidity of the refluxate. Moreover, a recent 5-
year follow-up of a randomized clinical trial using pH-measurements showed a lower 
level of pathologic acidity in the esophagus after surgery compared to medication in 
GERD patients.
31
 Finally, compared to medication, fundoplication is not dependent 
on dosage or compliance.  
 
In this study, the risk of developing EAC remained elevated in patients undergoing 
antireflux surgery compared to that of the background population. This could be 
explained by a particularly high severity of GERD in patients selected for antireflux 
surgery, where the DNA is already damaged, leaving the operated patients at a long-
term increased risk of EAC compared to the population at large. Moreover, the 
prevalence of Barrett’s esophagus is certainly higher in the antireflux surgery group 
than in the general population, and the Barrett’s mucosa does not disappear despite 
effective treatment of GERD. Furthermore, some of the patients undergoing antireflux 
surgery will have recurrence of GERD, again increasing the risk of EAC compared to 
the background population.
23, 32, 33
 Although, it might be that a reduction of the risk to 
that of the background population is not a reasonable goal due to the fact that many 
patients already have a premalignant condition. However, this is seldom the goal of 
other disease preventive measurements, where the aim usually is a risk reduction 
compared to alternative therapies or no treatment, rather than a reduction to the level 
of the background population. 
 
This meta-analysis suggests that antireflux surgery could be beneficial for patients 
with Barrett’s esophagus from a cancer preventive perspective, although uncertainty 
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remains. A recent Cochrane review concluded that both health-related quality of life 
and GERD-specific quality of life are improved after surgery compared to 
medication. Future research will show whether antireflux surgery should be 
recommended more frequently, for example, to young patients with Barrett´s 
esophagus.
34
 Especially if severity of dysplasia, and therefore future risk of EAC can 
be assessed (either through gastroscopy and pathology, or biochemistry) a population 
where a stronger EAC preventive effect could be seen might identified. Performing a 
RCT large enough to assess and compare the risk of EAC following surgery and 
medication would mean large methodological, logistic, and ethical difficulties. 
Therefore, other study designs, such as cohort studies or matched cohorts might be 
more feasible. 
 
In conclusion, this systematic review and meta-analysis provides some evidence that 
antireflux surgery may prevent EAC better than medication in patients with Barrett’s 
esophagus, while no such association was found for GERD patients without Barrett’s. 
An increased risk of EAC seems to remain long after antireflux surgery compared to 
the background population, which might be due to a higher prevalence of Barrett’s 
esophagus. These results must be interpreted cautiously since they are based on a 
limited sample size and might be affected by bias from severity and duration of 
GERD, confounding and chance errors. Hence there is a need for larger studies with 
longer follow-up that take confounding and severity of GERD into account, either by 
pathologic or molecular assessment of severity.  
15 
 
 
 
References: 
1. Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal 
reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 
340:825-831. 
2. Spechler SJ. Barrett esophagus and risk of esophageal cancer: a clinical 
review. JAMA 2013; 310:627-636. 
3. Edgren G, Adami HO, Weiderpass E, et al. A global assessment of the 
oesophageal adenocarcinoma epidemic. Gut 2013; 62:1406-1414. 
4. Lagergren J, Lagergren P. Recent developments in esophageal 
adenocarcinoma. CA Cancer J Clin 2013; 63:232-248. 
5. Hinder RA, Filipi CJ, Wetscher G, et al. Laparoscopic Nissen fundoplication 
is an effective treatment for gastroesophageal reflux disease. Ann Surg 1994; 
220:472-481; discussion 481-473. 
6. Laine S, Rantala A, Gullichsen R, et al. Laparoscopic vs conventional Nissen 
fundoplication. A prospective randomized study. Surg Endosc 1997; 11:441-
444. 
7. Eshraghi N, Farahmand M, Soot SJ, et al. Comparison of outcomes of open 
versus laparoscopic Nissen fundoplication performed in a single practice. Am 
J Surg 1998; 175:371-374. 
8. Corey KE, Schmitz SM, Shaheen NJ. Does a surgical antireflux procedure 
decrease the incidence of esophageal adenocarcinoma in Barrett's esophagus? 
A meta-analysis. Am J Gastroenterol 2003; 98:2390-2394. 
9. Chang EY, Morris CD, Seltman AK, et al. The effect of antireflux surgery on 
esophageal carcinogenesis in patients with barrett esophagus: a systematic 
review. Ann Surg 2007; 246:11-21. 
16 
 
 
 
10. Csendes A. Results of antireflux surgery in patients with Barrett's esophagus. 
European Surgery-Acta Chirurgica Austriaca 2008; 40:154-164. 
11. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic 
reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 
6:e1000097. 
12. Sanderson S, Tatt ID, Higgins JP. Tools for assessing quality and 
susceptibility to bias in observational studies in epidemiology: a systematic 
review and annotated bibliography. Int J Epidemiol 2007; 36:666-676. 
13. R Core Team. R: A language and environment for statistical computing. R 
Foundation for Statistical Computing, Vienna, Austria. 2014. 
14. Viechtbauer W. Conducting meta-analyses in R with the metafor package. 
Journal of Statistical Software 2010; 36:1-48. 
15. Bagos PG, Nikolopoulos GK. Mixed-Effects Poisson Regression Models for 
Meta-Analysis of Follow-Up Studies with Constant or Varying Durations. 
International Journal of Biostatistics 2009; 5. 
16. Kauttu TM, Rantanen TK, Sihvo EI, et al. Esophageal adenocarcinoma arising 
after antireflux surgery: a population-based analysis. Eur J Cardiothorac Surg 
2011; 40:1450-1454; discussion 1454. 
17. Lagergren J, Ye W, Lagergren P, et al. The risk of esophageal 
adenocarcinoma after antireflux surgery. Gastroenterology 2010; 138:1297-
1301. 
18. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-
analyses. BMJ 2003; 327:557-560. 
19. Williamson WA, Ellis FH, Jr., Gibb SP, et al. Effect of antireflux operation on 
Barrett's mucosa. Ann Thorac Surg 1990; 49:537-541; discussion 541-532. 
17 
 
 
 
20. McCallum RW, Polepalle S, Davenport K, et al. Role of anti-reflux surgery 
against dysplasia in Barrett's esophagus. Gastroenterology 1991:A121. 
21. Attwood SE, Barlow AP, Norris TL, et al. Barrett's oesophagus: effect of 
antireflux surgery on symptom control and development of complications. Br 
J Surg 1992; 79:1050-1053. 
22. Gurski RR, Peters JH, Hagen JA, et al. Barrett's esophagus can and does 
regress after antireflux surgery: a study of prevalence and predictive features. 
J Am Coll Surg 2003; 196:706-712; discussion 712-703. 
23. Tran T, Spechler SJ, Richardson P, et al. Fundoplication and the risk of 
esophageal cancer in gastroesophageal reflux disease: a Veterans Affairs 
cohort study. Am J Gastroenterol 2005; 100:1002-1008. 
24. Oberg S, Wenner J, Johansson J, et al. Barrett esophagus: risk factors for 
progression to dysplasia and adenocarcinoma. Ann Surg 2005; 242:49-54. 
25. Gatenby PA, Ramus JR, Caygill CP, et al. Treatment modality and risk of 
development of dysplasia and adenocarcinoma in columnar-lined esophagus. 
Dis Esophagus 2009; 22:133-142. 
26. Ye W, Chow WH, Lagergren J, et al. Risk of adenocarcinomas of the 
esophagus and gastric cardia in patients with gastroesophageal reflux diseases 
and after antireflux surgery. Gastroenterology 2001; 121:1286-1293. 
27. Spechler SJ, Lee E, Ahnen D, et al. Long-term outcome of medical and 
surgical therapies for gastroesophageal reflux disease: follow-up of a 
randomized controlled trial. JAMA 2001; 285:2331-2338. 
28. Parrilla P, Martinez de Haro LF, Ortiz A, et al. Long-term results of a 
randomized prospective study comparing medical and surgical treatment of 
Barrett's esophagus. Ann Surg 2003; 237:291-298. 
18 
 
 
 
29. Singh S, Garg SK, Singh PP, et al. Acid-suppressive medications and risk of 
oesophageal adenocarcinoma in patients with Barrett's oesophagus: a 
systematic review and meta-analysis. Gut 2014; 63:1229-1237. 
30. Jurgens S, Meyer F, Spechler SJ, et al. The role of bile acids in the neoplastic 
progression of Barrett's esophagus - a short representative overview. Z 
Gastroenterol 2012; 50:1028-1034. 
31. Galmiche JP, Hatlebakk J, Attwood S, et al. Laparoscopic antireflux surgery 
vs esomeprazole treatment for chronic GERD: the LOTUS randomized 
clinical trial. JAMA 2011; 305:1969-1977. 
32. Lofdahl HE, Lu Y, Lagergren P, et al. Risk factors for esophageal 
adenocarcinoma after antireflux surgery. Ann Surg 2013; 257:579-582. 
33. Lagergren J, Viklund P. Is esophageal adenocarcinoma occurring late after 
antireflux surgery due to persistent postoperative reflux? World J Surg 2007; 
31:465-469. 
34. Wileman SM, McCann S, Grant AM, et al. Medical versus surgical 
management for gastro-oesophageal reflux disease (GORD) in adults. 
Cochrane Database Syst Rev 2010:CD003243. 
 
  
19 
 
 
 
Figure 1. Search strategy used in this systematic review and numbers of eligible studies in 
each stage. 
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Table 1. Included studies, number of patients, total follow-up times and number of cases of esophageal adenocarcinoma (EAC) in this meta-analysis. 
Reference Year Country Type of study N of patients Type of surgery Type of medication Follow-up (person-
years) 
Mean (max) 
follow-up in years 
HGD/EAC 
Lagergren et al. 2010 Sweden Population-based 14102 ARS NF, partial fundoplication N/A 120514 8.5 (42) 0/39 
Kauttu et al. 2011 Finland Population-based 17643 ARS NF/partial fundoplication, Roux-en-Y 
reconstruction 
N/A 134438 7.6 (unknown) 0/29 
Williamson et al. 1990 USA Cohort 37 ARS 
142 MT 
NF ,Collis gastroplasty 
 
N/A 144  
198  
3.9 (unknown) 
1.4 (unknown) 
0/3 
0/2 
McCallum et al. 1991 USA Cohort 29 ARS 
152 MT 
NF, Hill gastropexy, Belsey procedure N/A 150  
621  
5.2 (unknown) 
4.1 (unknown) 
0/0 
0/2 
Attwood et al. 1992 Ireland Cohort 19 ARS 
26 MT 
Partial anterior fundoplication 
 
H2RA 57  
78  
3 (9) 
3 (9) 
0/1 
0/1 
Spechler et al. 2001 USA Randomized 
controlled study 
71 ARS 
137 MT 
NF 
 
H2RA, PPI, 
metoclopramide, sucralfate 
646  
1452  
9.1 (unknown) 
10.6 (unknown) 
0/1 
0/4 
Ye et al. 2001 Sweden Cohort 11077 ARS 
66965 UR 
N/A Unknown 86996 
376622  
7.8 (unknown) 
5.7 (unknown) 
0/43 
0/200 
Gurski et al. 2003 USA Cohort 77 ARS 
14 MT 
NF, partial fundoplication 
 
PPI 323  
59  
4.2 (unknown) 
4.2 (unknown) 
3/0 
1/0 
Parrilla et al. 2003 Spain Randomized 
controlled study 
58 ARS 
43 MT 
NF, Collis-Nissen procedure 
 
PPI 406  
258  
7 (18) 
6 (18) 
2/0 
2/0 
Oberg et al. 2005 Sweden Cohort 46 ARS 
94 MT 
NF, Hill gastropexy, partial 
fundoplication 
H2RA, PPI 347  
599  
7.5 (11.5) 
6.4 (8.2) 
0/0 
6/1 
Tran et al. 2005 USA Cohort 946 ARS 
1892 MT 
Fundoplication N/A 11156  
20115  
11.8 (unknown) 
10.6 (unknown) 
0/8 
0/8 
Gatenby et al 2009 UK Cohort 41 ARS 
697 MT 
N/A 
 
H2RA, PPI 254  
3457  
6.19 (unknown) 
4.96 (unknown) 
0/0 
10/20 
 
ARS antireflux surgery, N/A not applicable, HGD high grade dysplasia, RCT randomized controlled trial, MT medical treatment,  NF Nissen fundoplication (Total 
fundoplication), H2RA H2-receptor-antagonist, PPI Proton pump inhibitors.
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Figure 2. Characteristics and quality assessment of all 12 included studies in this meta-analysis. 
 
 
* Excluding 3 studies with non-medicated patients as comparison. 
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Figure 3. Forrest plot comparing the risk of esophageal adenocarcinoma after 
antireflux surgery and medical treatment in patients with gastro-esophageal reflux 
disease with and without Barrett’s esophagus. 
 
FE=Fixed-effects 
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Figure 4. Forrest plot comparing antireflux surgery to an unselected corresponding 
background population and risk of esophageal adenocarcinoma in this meta-analysis.  
 
FE=Fixed-effects 
 
 
 
